ES2071484T3 - Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral. - Google Patents

Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.

Info

Publication number
ES2071484T3
ES2071484T3 ES92903632T ES92903632T ES2071484T3 ES 2071484 T3 ES2071484 T3 ES 2071484T3 ES 92903632 T ES92903632 T ES 92903632T ES 92903632 T ES92903632 T ES 92903632T ES 2071484 T3 ES2071484 T3 ES 2071484T3
Authority
ES
Spain
Prior art keywords
derivatives
diaminoquinazolinas
antitumoral activity
increase
increase antitumoral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92903632T
Other languages
English (en)
Inventor
Jotham W Coe
Anton F J Fliri
Takushi Kaneko
Eric R Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2071484T3 publication Critical patent/ES2071484T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE 2,4 AUMENTAN LA EFECTIVIDAD DE AGENTES QUIMIOTERAPEUTICOS EN EL TRATAMIENTO DEL CANCER.
ES92903632T 1991-02-20 1992-01-08 Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral. Expired - Lifetime ES2071484T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20

Publications (1)

Publication Number Publication Date
ES2071484T3 true ES2071484T3 (es) 1995-06-16

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92903632T Expired - Lifetime ES2071484T3 (es) 1991-02-20 1992-01-08 Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.

Country Status (23)

Country Link
EP (1) EP0572437B1 (es)
JP (1) JPH06500117A (es)
KR (1) KR930703270A (es)
CN (1) CN1064271A (es)
AT (1) ATE121735T1 (es)
AU (1) AU655798B2 (es)
BR (1) BR9205645A (es)
CA (1) CA2101542A1 (es)
CZ (1) CZ387292A3 (es)
DE (2) DE69202243T2 (es)
DK (1) DK0572437T3 (es)
ES (1) ES2071484T3 (es)
FI (1) FI933656L (es)
HU (1) HUT64755A (es)
IE (1) IE920522A1 (es)
IL (1) IL100942A0 (es)
MX (1) MX9200675A (es)
NO (1) NO932954D0 (es)
NZ (1) NZ241627A (es)
PT (1) PT100132A (es)
WO (1) WO1992014716A1 (es)
YU (1) YU17092A (es)
ZA (1) ZA921911B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4429026C2 (de) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay-Entfernungsinstrumentarium für Totalendoprothese
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU2001240150A1 (en) * 2000-03-13 2001-09-24 Chemrx Advanced Technologies, Inc. Quinazoline synthesis
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
CA2592900A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
AU2006204052A1 (en) * 2005-01-03 2006-07-13 Cytovia, Inc. Method of treating brain cancer
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2009518359A (ja) * 2005-12-07 2009-05-07 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン−２，４−ジアミン誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルの調節剤としてのそれらの使用
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
US20090004185A1 (en) * 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
CA2691932A1 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
JP2013530942A (ja) 2010-05-07 2013-08-01 カリフォルニア・インスティチュート・オブ・テクノロジー 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物
US11318137B2 (en) * 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
ZA921911B (en) 1993-08-19
AU655798B2 (en) 1995-01-12
CA2101542A1 (en) 1992-08-21
HU9302384D0 (en) 1993-11-29
KR930703270A (ko) 1993-11-29
BR9205645A (pt) 1994-06-07
NO932954L (no) 1993-08-19
NO932954D0 (no) 1993-08-19
JPH06500117A (ja) 1994-01-06
FI933656A7 (fi) 1993-08-19
FI933656A0 (fi) 1993-08-19
AU1184892A (en) 1992-09-15
WO1992014716A1 (en) 1992-09-03
YU17092A (sh) 1994-12-28
PT100132A (pt) 1993-05-31
DE69202243D1 (de) 1995-06-01
CN1064271A (zh) 1992-09-09
IL100942A0 (en) 1992-11-15
IE920522A1 (en) 1992-08-26
DE9290018U1 (de) 1993-10-14
HUT64755A (en) 1994-02-28
NZ241627A (en) 1993-06-25
MX9200675A (es) 1992-08-01
EP0572437B1 (en) 1995-04-26
FI933656L (fi) 1993-08-19
CZ387292A3 (en) 1994-04-13
DE69202243T2 (de) 1995-08-31
DK0572437T3 (da) 1995-07-03
ATE121735T1 (de) 1995-05-15
EP0572437A1 (en) 1993-12-08

Similar Documents

Publication Publication Date Title
MX9200675A (es) Derivados de 2,4-diaminoquinazolinas para mejorar la actividad antitumoral.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ES2191192T3 (es) Tienopirimidinas.
ES2179096T3 (es) Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
ATE185483T1 (de) Antivirale nucleosidkombination
LV10924A (lv) Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
PT933995E (pt) Metodo para tratamento de lesao endotelial
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
SE9701161D0 (sv) New use I
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
DK0520200T3 (da) Imadazol-forbindelser, deres fremstilling og anvendelse
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
ES2111891T3 (es) Empleo de l-carnitina o acil l-carnitinas y valproato para tratar trastornos epilepticos.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2058161T3 (es) Producto activo para la lucha contra tumores.
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 572437

Country of ref document: ES